|1.||Li, Yuan-Jian: 6 articles (03/2015 - 10/2006)|
|2.||Böger, Rainer H: 5 articles (04/2012 - 02/2008)|
|3.||Cooke, John P: 5 articles (02/2010 - 08/2002)|
|4.||Leiper, James: 4 articles (06/2015 - 08/2003)|
|5.||Jacobi, Johannes: 4 articles (01/2014 - 09/2005)|
|6.||Maas, Renke: 4 articles (01/2014 - 02/2008)|
|7.||Teerlink, Tom: 4 articles (04/2012 - 12/2003)|
|8.||van Leeuwen, Paul A M: 4 articles (04/2012 - 12/2003)|
|9.||Peng, Jun: 4 articles (11/2010 - 03/2008)|
|10.||Yuan, Qiong: 3 articles (03/2015 - 10/2006)|
07/01/2009 - "Dimethylarginine dimethylaminohydrolase in rat penile tissue: reduced enzyme activity is responsible for erectile dysfunction in a rat model of atherosclerosis."
05/01/2007 - "Decrease in activity of dimethylarginine dimethylaminohydrolase (DDAH), a major hydrolase of ADMA, causes accumulation of ADMA in some risk factors of atherosclerosis, including hypercholesterolemia. "
10/08/2010 - "Elevated endogenous asymmetric dimethylarginine (ADMA) is an independent risk factor for atherosclerosis, and dimethylarginine dimethylaminohydrolase (DDAH) is the key enzyme responsible for the metabolism of ADMA. "
05/01/2010 - "Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine."
01/01/2014 - "The purpose of the work was to study the impact of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) and its degrading enzyme, dimethylarginine dimethylaminohydrolase (DDAH1), on atherosclerosis in subtotally nephrectomized (SNX) ApoE-deficient mice. "
|2.||Hypertension (High Blood Pressure)
01/01/2012 - "However, data from small-sized clinical trials and experimental approaches using murine transgenic models have revealed conflicting results regarding the impact of ADMA and its metabolizing enzyme dimethylarginine dimethylaminohydrolase (DDAH) in the pathogenesis of hypertension. "
12/01/2009 - "Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension."
08/01/2003 - "Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase."
02/01/2008 - "The aim of the present study was to investigate the role of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and its degrading enzyme dimethylarginine dimethylaminohydrolase (DDAH) in angiotensin II (ANG II)-induced hypertension and target organ damage in mice. "
|3.||Coronary Disease (Coronary Heart Disease)
11/01/2012 - "Association study of dimethylarginine dimethylaminohydrolase 2 gene polymorphisms and coronary heart disease."
04/02/2010 - "In the present study, we tested whether a novel genetic variant in dimethylarginine dimethylaminohydrolase 1 (DDAH1), an important ADMA hydrolyzing gene, was associated with stroke and coronary heart disease (CHD) susceptibility in the Chinese Han population. "
11/01/2011 - "Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas."
09/09/2002 - "To study the effect of dimethylarginine dimethylaminohydrolase on tumour growth and vascular development, the rat C6 glioma cell line was manipulated to overexpress the rat gene for dimethylarginine dimethylaminohydrolase I. Enhanced expression of dimethylarginine dimethylaminohydrolase I increased nitric oxide synthesis (as indicated by a two-fold increase in the production of cGMP), expression and secretion of vascular endothelial cell growth factor, and induced angiogenesis in vitro. "
07/01/2004 - "The oxygenation status of tumors derived from wild-type C6 glioma cells and clone D27 cells overexpressing dimethylarginine dimethylaminohydrolase (DDAH) was assessed in vivo using a variety of direct and indirect assays of hypoxia. "
08/15/2003 - "Overexpression of dimethylarginine dimethylaminohydrolase (DDAH), which metabolizes the endogenous inhibitors of NO synthesis asymmetric dimethylarginine and N-monomethyl-L-arginine, results in C6 gliomas with enhanced growth rate compared with wild type. "
|5.||Septic Shock (Toxic Shock Syndrome)
11/01/2012 - "Genetic and pharmacological inhibition of dimethylarginine dimethylaminohydrolase 1 is protective in endotoxic shock."
01/01/2006 - "Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study."
|1.||N,N-dimethylarginine (asymmetric dimethylarginine)
|3.||Nitric Oxide Synthase (NO Synthase)
|5.||Nitric Oxide (Nitrogen Monoxide)
|7.||Apolipoproteins E (ApoE)